Increases focus on clinical development of GPCR-targeted drug candidates
Heptares Therapeutics, the a UK-based GPCR structure-guided drug discovery and development company, has appointed Tim Tasker as Chief Medical Officer (CMO) and Vice President of Development to lead the company’s clinical development activities. He takes over from David McGibney, who returns to his role as a senior clinical advisor to the company.
Tasker has more than 30 years of industry experience from both large pharmaceutical and small biotechnology companies. He spent over 20 years at GlaxoSmithKline and led all of its Phase 1 Clinical Research Units (in the US, UK, Europe and Australia). He then joined Evotec as Executive VP of Clinical Development, at which he advanced novel compounds to Phase II proof of concept studies.
Tasker later set up his own consultancy firm providing high-level, early drug development expertise to companies in Europe, Australia and Japan.